ZA202305665B - Model for predicting risk of small cell transformation in patient with lung adenocarcinoma and establishment method thereof - Google Patents
Model for predicting risk of small cell transformation in patient with lung adenocarcinoma and establishment method thereofInfo
- Publication number
- ZA202305665B ZA202305665B ZA2023/05665A ZA202305665A ZA202305665B ZA 202305665 B ZA202305665 B ZA 202305665B ZA 2023/05665 A ZA2023/05665 A ZA 2023/05665A ZA 202305665 A ZA202305665 A ZA 202305665A ZA 202305665 B ZA202305665 B ZA 202305665B
- Authority
- ZA
- South Africa
- Prior art keywords
- model
- small cell
- cell transformation
- patient
- risk
- Prior art date
Links
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title abstract 5
- 230000010307 cell transformation Effects 0.000 title abstract 5
- 201000005249 lung adenocarcinoma Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000010276 construction Methods 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 abstract 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 abstract 1
- 101150104237 Birc3 gene Proteins 0.000 abstract 1
- 102100024334 Collagen alpha-6(VI) chain Human genes 0.000 abstract 1
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 abstract 1
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 abstract 1
- 102100035960 Hedgehog-interacting protein Human genes 0.000 abstract 1
- 101710164669 Hedgehog-interacting protein Proteins 0.000 abstract 1
- 101000909495 Homo sapiens Collagen alpha-6(VI) chain Proteins 0.000 abstract 1
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 abstract 1
- 101000983515 Homo sapiens Inactive caspase-12 Proteins 0.000 abstract 1
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 abstract 1
- 102100026556 Inactive caspase-12 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 abstract 1
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 abstract 1
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000010841 mRNA extraction Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Disclosed are a model for predicting the risk of small cell transformation in a patient with lung adenocarcinoma (LUAD) and an establishment method thereof. The model for predicting the risk of small cell transformation in a patient with LUAD includes: detection of mRNA expression levels of COL6A6, CASP12, HHIP, ZBTB16, BIRC3, and GATA2 in a tumor sample of a patient with LUAD. The establishment method of the model includes: mRNA extraction and data processing, binary classification of continuous variables, and variable screening of binary variables and model construction. The model provided in the present disclosure is superior to single mRNA used for model construction in the accuracy of diagnosis of the risk of small cell transformation in patients. Moreover, the model constructed in the present disclosure is helpful for individualized management of patients. For patients with high scores, i.e., patients at high risk of transformation, the frequency of drug resistance monitoring should be increased, and if necessary, secondary biopsy should be performed to determine whether small cell transformation occurs, thereby effectively guiding clinical application.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211419631.8A CN115637292B (en) | 2022-11-14 | 2022-11-14 | Model for predicting small cell transformation risk of lung adenocarcinoma patient and establishing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202305665B true ZA202305665B (en) | 2024-01-31 |
Family
ID=84948983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/05665A ZA202305665B (en) | 2022-11-14 | 2023-05-24 | Model for predicting risk of small cell transformation in patient with lung adenocarcinoma and establishment method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115637292B (en) |
| ZA (1) | ZA202305665B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110119776A1 (en) * | 2007-02-05 | 2011-05-19 | Wong Kwok-Kin | Methods of diagnosing and prognosing lung cancer |
| CN109136370A (en) * | 2018-05-31 | 2019-01-04 | 广州表观生物科技有限公司 | A kind of prognostic markers object of lung cancer and its application |
| EP4247980A2 (en) * | 2020-11-19 | 2023-09-27 | Tempus Labs, Inc. | Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment |
| CN112635063B (en) * | 2020-12-30 | 2022-05-24 | 华南理工大学 | Comprehensive lung cancer prognosis prediction model, construction method and device |
| CN113373220A (en) * | 2021-05-08 | 2021-09-10 | 首都医科大学 | Marker molecules associated with prognosis of non-small cell lung cancer |
-
2022
- 2022-11-14 CN CN202211419631.8A patent/CN115637292B/en active Active
-
2023
- 2023-05-24 ZA ZA2023/05665A patent/ZA202305665B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115637292B (en) | 2023-03-10 |
| CN115637292A (en) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horn et al. | Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia | |
| US11640661B2 (en) | System and method for predicting the risk of future lung cancer | |
| CN109830264B (en) | Method for classifying tumor patients based on methylation sites | |
| NZ593225A (en) | Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis | |
| Wang et al. | Multidimensional cell-free DNA fragmentomic assay for detection of early-stage lung cancer | |
| CN108588230A (en) | A kind of marker and its screening technique for breast cancer diagnosis | |
| Deilhes et al. | Advanced cutaneous squamous cell carcinoma is associated with suboptimal initial management in a cohort of 109 patients | |
| CN110911008A (en) | Method for establishing biliary tract occluded alignment chart prediction model and application thereof | |
| Qian et al. | Novel multiple miRNA-based signatures for predicting overall survival and recurrence-free survival of colorectal cancer patients | |
| ZA202305665B (en) | Model for predicting risk of small cell transformation in patient with lung adenocarcinoma and establishment method thereof | |
| Men et al. | A prognostic 11 genes expression model for ovarian cancer | |
| Thong et al. | Accuracy of self-reported smoking exposure among bladder cancer patients undergoing surveillance at a tertiary referral center | |
| CN111063435A (en) | Diabetes typing diagnosis system | |
| CN110570951A (en) | Method for constructing classification model of new auxiliary chemotherapy curative effect of breast cancer | |
| CN109182524A (en) | MiRNA combination marker and its application of a kind of auxiliary diagnosis cervical carcinoma and its precancerous lesion | |
| CN101423869B (en) | Biomarker for detection and application | |
| MX2022013833A (en) | Methods for identifying a medical condition in a human subject. | |
| Li et al. | Integrated network analysis to determine CNN1, MYL9, TAGLN, and SORBS1 as potential key genes associated with prostate cancer | |
| Di Caro et al. | Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: comparison and combination of cell and cell-free platforms | |
| Tarasova et al. | Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing | |
| Garajová et al. | Comment on “Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma by Crippa et al.” | |
| Gupta et al. | Framingham heart study | |
| Silvestri | PIERCE: Pipeline to InfER Cancer Evolution through circulating tumor cells in cholangiocarcinoma patients | |
| CN106636450A (en) | Non-invasive marker and kit for diagnosis of lung squamous cell carcinoma patients among non-smoking or mild-smoking people | |
| Ge et al. | Effect of phenotypic detection of circulating tumor cells marked by epithelial-mesenchymal transformation on the prognosis of lung cancer: A protocol for systematic review and meta-analysis |